Literature DB >> 16454884

Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption.

Astrid E Lammers1, Sheila G Haworth, Christine M Pierce.   

Abstract

Oral sildenafil has been demonstrated to be an effective treatment for pulmonary hypertension, and is increasingly used in children. We report an infant with pulmonary hypertension, stable on regular treatment with oral sildenafil, who presented in acute respiratory failure after aspiration, requiring ventilation and intensive care. The course of the stay in intensive care was difficult, with recurrent pulmonary hypertensive crises despite use of oral sildenafil, use of 100% oxygen, high frequency oscillatory ventilation, and inhaled nitric oxide. In view of his instability, and the presumed inability to absorb the sildenafil orally due to gastrointestinal malabsorption, sildenafil was administered as a continuous intravenous infusion. With this therapy, it proved possible to wean from oxygen, nitric oxide, and ventilatory support. Intravenous sildenafil, therefore, might be an effective alternative for children with pulmonary hypertension during episodes of acute deterioration and malabsorption, preventing life-threatening pulmonary hypertensive crises. Its pharmacokinetics, efficacy, and safety, nonetheless, need to be validated in randomized controlled trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16454884     DOI: 10.1017/S1047951105002155

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  7 in total

1.  Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.

Authors:  Jean-Luc Vachiery; Sandrine Huez; Hunter Gillies; Gary Layton; Naoto Hayashi; Xiang Gao; Robert Naeije
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

Review 2.  Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease.

Authors:  Monnipa Suesaowalak; John P Cleary; Anthony C Chang
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

Review 3.  Sildenafil for the treatment of pulmonary hypertension in pediatric patients.

Authors:  Alice J Huddleston; Chad A Knoderer; Jennifer L Morris; Eric S Ebenroth
Journal:  Pediatr Cardiol       Date:  2009-08-25       Impact factor: 1.655

Review 4.  Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery.

Authors:  Nathan Brunner; Vinicio A de Jesus Perez; Alice Richter; François Haddad; André Denault; Vanessa Rojas; Ke Yuan; Mark Orcholski; Xiaobo Liao
Journal:  Pulm Circ       Date:  2014-03       Impact factor: 3.017

5.  Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease.

Authors:  Alain Fraisse; Ghazwan Butrous; Mary B Taylor; Michael Oakes; Maria Dilleen; David L Wessel
Journal:  Intensive Care Med       Date:  2010-11-11       Impact factor: 17.440

Review 6.  Sildenafil in pediatric pulmonary arterial hypertension.

Authors:  A K Dhariwal; S B Bavdekar
Journal:  J Postgrad Med       Date:  2015 Jul-Sep       Impact factor: 1.476

7.  Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports.

Authors:  Alexandra Carls; Julia Winter; Yeliz Enderle; Jürgen Burhenne; Matthias Gorenflo; Walter E Haefeli
Journal:  J Med Case Rep       Date:  2014-05-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.